immune control siv challenge t-cell-based vaccine rhesus monkeys
recombinant adenovirus serotype rad5 vector based vaccine hiv recently failed phase 2b efficacy study humans consistent results preclinical studies demonstrated rad5 vectors expressing simian immunodeficiency virus siv gag failed reduce peak setpoint viral loads siv challenge rhesus monkeys macaca mulatta lacked protective mhc class allele mamu-a* ref show improved t cell based vaccine regimen using two serologically distinct adenovirus vectors afforded substantially improved protective efficacy challenge model particular heterologous rad26 prime/rad5 boost vaccine regimen expressing siv gag elicited cellular immune responses augmented magnitude breadth polyfunctionality compared homologous rad5 regimen sivmac251 challenge monkeys vaccinated rad26/rad5 regimen showed log reduction peak log reduction setpoint viral loads well decreased aids related mortality compared control animals data demonstrate durable partial immune control pathogenic siv challenge days can achieved t cell based vaccine mamu-a*-negative rhesus monkeys absence homologous env antigen findings important implications development next generation t cell based vaccine candidates hiv
